Breast cancer is the most frequently observed cancer in women in France.The mortality rate is still decreasing with a decrease of 1.6% per year between 2010 and 2018, explained by the improvement in available treatments.For patients with breast cancer expressing hormone receptors, treatment with Tamoxifen or anti-aromatase can have the risk of the cancer coming back.However, these treatments have many side effects, including the risk of osteoporosis and metabolic disorders with anti-aromatases; and arterial and thromboembolic accidents with Tamoxifen.These effects have been well studied while taking hormone therapy.However, very few studies have analyzed the impact of these treatments after stopping them in women who have had non-metastatic hormone-sensitive breast cancer and uncertainties persist on the evolution of the health risk after initial treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
102
A questionnaire will be given to patients who will ask them about their possible fractures, their bone and oncological follow-ups and their possible cardiovascular events since the end of treatment with hormone therapy.
CHU Toulouse
Toulouse, France
Evaluate the bone impact of hormone therapy remotely
A questionnaire asking patients if they have fractures since stopping the treatment will be offered.
Time frame: Inclusion day (day 0)
Evaluate the cardiovascular impact of hormone therapy remotely
A questionnaire asking patients if they have had a cardiovascular problem since stopping treatment will be offered.
Time frame: Inclusion day (day 0)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.